GLP-1s do not cause major psychiatric harm, according to new study
A comprehensive review by researchers at New Mexico State University and UNLV found no evidence linking GLP-1 receptor agonist medications to increased psychiatric risks. The study supports the safety of popular drugs like Ozempic and Wegovy regarding mental health.
Why it matters
This provides clarity for millions of patients using these medications for diabetes and obesity, potentially reducing stigma and anxiety surrounding their use.
by Carlos Andres López, New Mexico State University
edited by Lisa Lock , reviewed by Andrew Zinin
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add as preferred source Credit: Unsplash/CC0 Public Domain There is no link between the widely used diabetes and obesity medications known as GLP-1 receptor agonists and increased suicidal thoughts, depression or other serious psychiatric harm, based on an integrative review of current scientific evidence conducted by researchers at New Mexico State University and the University of Nevada, Las Vegas.
The review, published in the journal Diabetology , traced the earliest concerns raised over GLP-1 RA therapies and found that, after subsequent investigations, the medications do not increase psychiatric risk. GLP-1s include medications such as Ozempic, Wegovy, Saxenda and Zepbound.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in